Abstract
after the administration of anesthetic sevoflurane [1-, 1.5-and 2-fold minimum alveolar 48 concentration] at 37 0 C. The total walking distance and velocity of movement were measured and 49 quantified as the indexes of locomotion. We found that the anesthetic sevoflurane increased the 50 locomotion of the mice during the induction of the anesthesia. During the recovery phase after 51 anesthesia, the mice exhibited increased locomotion for a short period of time (about 5 minutes) 52 and then displayed a sharp decrease in mobility for up to 60 minutes following the end of 53 anesthesia administration. The anesthetic sevoflurane did not significantly alter the food intake 54 and body weight of the mice. Furthermore, we found that Alzheimer's disease transgenic mice 55 exhibited a greater sevoflurane-induced hyperactivity than the wild-type mice did. Our results
56
showed that inhalation of the anesthetic sevoflurane induced an acute hyperactivity in mice, 57 particularly among Alzheimer's disease transgenic mice. These findings from the pilot studies hyperactivity and the underlying mechanisms of these conditions.
Introduction

65
Sevoflurane is one of the most commonly used general anesthetics. Despite 13, 14 . However, the acute behavioral change in locomotion following the administration of 83 the anesthetic sevoflurane has not been fully elucidated. Therefore, the objective of the present 84 study was to establish a system to assess the acute effects of sevoflurane on locomotion in mice.
85
The hypothesis in the current studies was that the anesthetic sevoflurane increased locomotion in to minimize the number of mice that were used in experiments. The study was performed on WT
138
C57BL/6J and AD Tg 9 month-old female mice (Jackson Lab, Bar Harbor, ME). The AD Tg 
Anesthesia in mice 144
Prior to carrying out the experiments, we familiarized the mice to the transparent gas- between 9:00 a.m. and 12:00 p.m. Then, the mice were placed into the chamber and exposed to 148 sevoflurane for 30 minutes (for locomotion activity assessment), for 4-hours (for food intake and 149 gain weight assessment) or to the control condition. We used air containing 40% O 2 /60% N 2 as a 150 carrier, the total gas flow was 2 l/min. During the exposure to anesthesia, the mice were kept 151 warm on a plate heated to 37°C with a white colored background. Control and experimental 6 152 animals were exposed to the same environmental conditions except that the control animals were 153 exposed only to air. The Dash 4000 monitor (GE Medical Systems information technologies 154 INC., Wisconsion, USA) was used to determine the concentrations of sevoflurane.
155
Locomotion measurement
156
While their horizontal ambulatory activity was measured with the aid of a video-tracking 157 system, the animals were allowed to move freely in the transparent gas-tight plastic chamber.
158
This allowed us to measure all the required parameters offline in simple blind conditions using
159
ImageJ Plugin. The mouse activity was recorded before (5 minutes in air as baseline tracks), 160 during (30 minutes) and after the sevoflurane anesthesia (40-minutes recovery). Here, we used 1-161 , 1.5-and 2-fold minimum alveolar concentrations (MAC), which correspond to 2, 3, and 4% of 162 sevoflurane respectively at 37 0 C 1,3,15 . The total walking distance (in cm) and velocity (in 163 cm/min) of movement were measured and quantified as indexes of hyperactivity.
164
Following the experimental session, the mice were carefully removed from the chamber, 165 and returned to their home cage. The test equipment was cleaned with 50% ethanol solution and 166 dried between subjects in order to avoid olfactory cuing. A sample size of 4-9 mice was used for 167 each group and all the mice were used only once.
168
Food intake and body weight 169 The food intake and body weight were measured after daily anesthesia exposure between 
224
The sevoflurane-induced hyperactivity was greater in AD Tg mice.
225
Recent in vivo evidence from mouse models and human patients have indicated that, 226 particularly in early stages of AD, neuronal circuits are hyperactive instead of hypoactive 8-11 , 227 which could lead to key complications in AD 12 . Therefore, we questioned how sevoflurane-228 induced movement in AD Tg mice.
229
To answer this question, we performed further experiments using AD Tg mice. Figure 3A 
230
shows that the sevoflurane-induced hyperactivity in AD Tg mice was greater than that of the WT 231 mice (342.60 ± 42.43 cm/min for AD Tg mice versus 247.94 ± 36.83 cm/min for WT mice).
232
Given the findings that the baseline velocity of mice was different, we calculated the ratio of Figures 3B and 3C ).
235
We found that the ratios of velocity and walking distance were still significantly higher in AD Tg anesthesia. These data demonstrate that the anesthetic sevoflurane did not significantly change 246 the food intake and body weight of the mice. Thus, the paradox is that higher levels of hippocampal activity may drive AD disease progress 12 290 and may be early indicators of AD-related neurodegeneration 11, 23 . Our data showed that 291 sevoflurane induced greater hyperactivity in AD Tg mice than in WT mice. However, the exact 292 the mechanism and the clinical relevance of such findings need to be further investigated.
293
Our study has several limitations. First, we did not demonstrate the concentration- 
